StockData
Janux Therapeutics, Inc. logo

Janux Therapeutics, Inc. (JANX) company profile

JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3035% below fair value
$10.71−0.21 (-1.92%)

Close on Nov 17, 2026Market cap $654.78MP/E –Yield –

About Janux Therapeutics

Pharmaceutical Preparations, SIC 2834

Janux Therapeutics is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer and autoimmune conditions. The company utilizes its proprietary TRACTr, TRACIr, and ARM technology platforms to create engineered bispecific molecules and T cell engagers. Its main clinical-stage candidates include JANX007, an investigational TRACTr therapy designed to treat metastatic castration-resistant prostate cancer, and JANX008, an EGFR-targeting TRACTr being evaluated across various solid tumor indications. In addition, the firm is advancing JANX011 for autoimmune diseases. While its clinical candidates are designed to treat patients, the company also engages with large biopharmaceutical collaborators such as Merck Sharp & Dohme and Bristol Myers Squibb.

The company's pipeline assets undergo clinical and nonclinical evaluation across multiple study cohorts and indications, though the text does not disclose operational metrics, facility counts, geographic footprints, or the location of its corporate headquarters.

Summary of the business section of Janux Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Janux Therapeutics, Inc.
Headquarters
San Diego, CA
Address
10955 Vista Sorrento Parkway, Suite 200 92130
Phone
(858) 751-4493
Employees
109, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Diego, California

Stock & identifiers

Ticker
JANX
Exchange
Nasdaq
IPO date
Jun 11, 2021
Shares outstanding
61M, Aug 4, 2026
Public float
$1.10B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1817713
CUSIP
47103J105
ISIN
US47103J1051
FIGI
BBG00ZHSKH11
Share class FIGI
BBG00ZHSKH39
EIN
82-2289112

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
David Alan CampbellPresident and CEO, Director264,742
Janeen Noel DoyleChief Corp. & Bus. Dev. Ofcr75,941
Maria DobekVice President, Accounting32,270
William GoChief Medical Officer44,000
Andrew Hollman MeyerChief Business Officer83,095
Charles M. WinterChief Technical Officer77,721
Thomas DiRaimondoChief Scientific Officer155,825
Zachariah McIverChief Medical Officer23,286
Byron RobinsonChief Strategy Officer28,000
Vickie L. CappsDirector79,598
Jake SimsonDirector11,750
Capital Healthcare Fund LP RADirector6,250
Ronald W. BarrettDirector11,750
Eric DobmeierDirector15,481
RA Capital Nexus Fund II, L.P.Director11,750
Winston KungDirector11,750
Rajeev M. ShahDirector–
Peter KolchinskyDirector9,317,246
Natasha HerndayDirector15,481
Ra Capital Management, L.P.Director2,500
Alana B. McNultyDirector6,250
Sheila GujrathiDirector118,889

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$13.51M-$17.75M$4.61M$105$135
FY2024$8.97M$55.19M$5.05M$407$102
FY2023$4.19M$1.05M$1.67M$81$104

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
David Campbell
President and Chief Executive Officer
$680.00K––$12.46M$367.20K–$13.51M+50%
Thomas DiRaimondo
Chief Scientific Officer
$478.00K––$3.69M$175.90K–$4.35M+27%
Janeen Doyle
Chief Corporate and Business Development Officer
$309.96K$75.00K$995.28K$3.12M$114.07K$50.00K$4.67M–
Zachariah McIver
Former Chief Medical Officer
$475.00K––$4.00M$165.30K–$4.64M–
Byron Robinson
Former Chief Strategy Officer
$362.73K––$4.31M–$394.08K$5.06M+33%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 11, 2021
Offer price
$17.00
Securities offered
11,400,000
Gross proceeds
$193.80M
Exchange
Nasdaq
First trading day
Jun 11, 2021
First-day close
$25.15+47.9%
Lock-up ends (est.)
Dec 8, 2021

“Per Share Total Initial public offering price $ 17.00 $ 193,800,000 Underwriting discounts and commissions (1) $ 1.19 $ 13,566,000 Proceeds, before expenses, to us $ 15.81 $ 180,234,000 (1) See the section titled “Underwriting” for a description of the compensation payable to the underwriters.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 109 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?